ONCOLOGY Nurse Edition October 2008, Vol 22 No 11

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Responses with epcoritamab were comparable across the expansion and optimization cohorts in the EPCORE CLL-1 trial.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Kelley A. Rone, DNP, RN, AGNP-c

December 2nd 2024

Revumenib-Based Regimen Demonstrates High Remission Rates in Relapsed/Refractory AML

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

$Revumenib-Based Regimen Demonstrates High Remission Rates in Relapsed/Refractory AML$

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Findings from the SAVE study showed that an all-oral revumenib-based combination may improve responses in patients with acute myeloid leukemia with certain genetic alterations.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Tanios S. Bekaii-Saab, MD, FACP

November 25th 2024

Genetic Mutations and Disease Progression in MDS Increased by Tobacco Smoking

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

DFS Improves Using Blinatumomab Combo in Pediatric Standard-Risk B-ALL

Smoking may contribute to genetic mutations and disease progression in myelodysplastic syndromes, a recent study found.

Blinatumomab plus chemotherapy may represent a new treatment standard for most patients with standard-risk B-ALL, says Rachel E. Rau, MD.

Ashling Wahner

Subcutaneous Epcoritamab Elicits Deep Responses in Heavily Pretreated CLL

Blinatumomab plus chemotherapy may represent a new treatment standard for most patients with standard-risk B-ALL, says Rachel E. Rau, MD.

Related Content

Gina Mauro

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Responses with epcoritamab were comparable across the expansion and optimization cohorts in the EPCORE CLL-1 trial.

Kelley A. Rone, DNP, RN, AGNP-c

December 2nd 2024

Revumenib-Based Regimen Demonstrates High Remission Rates in Relapsed/Refractory AML

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

$Revumenib-Based Regimen Demonstrates High Remission Rates in Relapsed/Refractory AML$

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Findings from the SAVE study showed that an all-oral revumenib-based combination may improve responses in patients with acute myeloid leukemia with certain genetic alterations.

Tanios S. Bekaii-Saab, MD, FACP

November 25th 2024

Genetic Mutations and Disease Progression in MDS Increased by Tobacco Smoking

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

DFS Improves Using Blinatumomab Combo in Pediatric Standard-Risk B-ALL

Smoking may contribute to genetic mutations and disease progression in myelodysplastic syndromes, a recent study found.

Ashling Wahner